Skip to Main Content

Biogen (BIIB) is going to buy back more of its own stock.

Any investor hoping for a more radical adjustment to the biotech’s strategic plan following the aducanumab failure — the Alzheimer’s drug setback triggered a $20 billion loss in market value — has to be disappointed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!